Methicillin resistant Staphylococcus aureus: Is it a problem for nasal surgery?

Journal of Laryngology and Otology

Volumn 121, Issue 5, 2007, Pages 415-418

  Sharma, A ^a,b   Philpott, C ^a   Pope, L ^a   McKiernan, D ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b WEST SUFFOLK HOSPITAL   (United Kingdom)

Author keywords

Complication; Infection; Methicillin; Nose; Staphylococcus aureus

Indexed keywords

METICILLIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; BACTERIAL FLORA; CORYNEBACTERIUM DIPHTHERIAE; HUMAN; IMMUNE RESPONSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; NONHUMAN; NOSE CAVITY; NOSE SURGERY; POSTOPERATIVE INFECTION; REVIEW; STAPHYLOCOCCUS INFECTION; TOXIC SHOCK SYNDROME;

CARRIER STATE; HUMANS; METHICILLIN RESISTANCE; NOSE; NOSE DISEASES; POSTOPERATIVE COMPLICATIONS; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 34249700130     PISSN: 00222151     EISSN: 17485460     Source Type: Journal    
DOI: 10.1017/S0022215106002763     Document Type: Review

References (55)

1. Vos C, Verbrugh H. MRSA: We can overcome, but who will lead the battle? Infect Control Hosp Epidemiol 2005;26:117-20
2. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339:520-32
3. Lyell A. Alexander Ogston (1844-1929)-staphylococci. Scott Med J 1977;22:277-8
4. Department of Health. A simple guide to MRSA. About methicillin resistant staphylococcus aureus. November 2004. http://www.dh.gov.uk/ PolicyAndGuidance/HealthAndSocialCareTopics/HealthcareAcquiredInfection/ HealthcareAcquiredGeneralInformation/Healthcare AcquiredGeneralArticle/fs/en? CONTENT_ID=4093113 &chk=7/XgcQ [20 April 2005]
5. National Nosocomial Infections Surveillance System report: data summary from January 1992-January 2001. Am J Infect Control 2001;29:404-21
6. Steinberg JP, Clark CC, Hackman BO. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis 1996;23:255-9
7. Reacher MH, Shah A, Livermore DM, Wale MC, Graham C, Johnson AP et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. Br Med J 2000;320:213-16
8. Duckworth G. Controlling methicillin resistant staphylococcus aureus. Br Med J 2003;327:1177-8
9. Barrett SP, Spencer RC. MRSA bacteraemia surveillance scheme in England. J Hosp Infect 2002;50:241-2
10. Cluff LE, Reynolds RC, Page DL, Breckenridge JL. Staphylococcal bacteremia: demographic, clinical and microbiological features of 185 cases. Trans Am Clin Climatol Assoc 1968;79:205-15
11. Julander I, Svanbom M. Prediction of staphylococcal etiology among patients with septicemia with or without endocarditis by multivariate statistical methods. Scand J Infect Dis 1985;17:37-46
12. Wegner DL. No mercy for MRSA: treatment alternatives to vancomycin and linezolid. MLO Med Lab Obs 2005;37:26-9
13. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP et al. Infection with vancomycin-resistant staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348:1342-7
14. Entenza JM, Que YA, Vouillamoz J, Glauser MP, Moreillon P. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant staphylococcus aureus expressing various degrees of ciprofloxacin resistance. Antimicrob Agents Chemother 2001;45:3076-83
15. Gonzalez-Zorn B, Courvalin P. VanA-mediated high level glycopeptide resistance in MRSA. Lancet Infect Dis 2003;3:67-8
16. Malbruny B, Canu A, Bozdogan B, Fantin B, Zarrouk V, Dutka-Malen S et al. Resistance to quinupristin-dalfopristin due tomutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob Agents Chemother 2002;46:2200-7
17. Moore MR, Perdreau-Remington F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 2003;47:1262-6
18. Pillai SK, Sakoulas G, Wennersten C, Eliopoulos GM, Moellering RC Jr, Ferraro MJ et al. Linezolid resistance in staphylococcus aureus: characterization and stability of resistant phenotype. J Infect Dis 2002;186:1603-7
19. Solberg CO. Spread of staphylococcus aureus in hospitals: causes and prevention. Scand J Infect Dis 2000;32:587-95
20. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-402
21. Moise PA, Schentag JJ. Vancomycin treatment failures in staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 2000;16:31-4
22. Williams R. Healthy carriage of staphylococcus aureus, its prevalence and importance. Bacteriology Review 1963;27:56-71
23. Parras F, Guerrero MC, Bouza E, Blazquez MJ, Moreno S, Menarguez MC et al. Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant staphylococcus aureus. Antimicrob Agents Chemother 1995;39:175-9
24. Reagan DR, Doebbeling BN, Pfaller MA, Sheetz CT, Houston AK, Hollis RJ et al. Elimination of coincident staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med 1991;114:101-6
25. Armstrong-Esther CA. Carriage patterns of staphylococcus aureus in a healthy non-hospital population of adults and children. Ann Hum Biol 1976;3:221-7
26. Noble W, Williams R, Jevons M, Shooter RJCP. Some aspects of nasal carriage of staphylococci. 1964;17:79-83
27. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997;10:505-20
28. Luzar MA, Coles GA, Faller B, Slingeneyer A, Dah GD, Briat C et al. staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N Engl J Med 1990;322:505-9
29. Yu VL, Goetz A, Wagener M, Smith PB, Rihs JD, Hanchett J et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med 1986;315:91-6
30. Nguyen MH, Kauffman CA, Goodman RP, Squier C, Arbeit RD, Singh N et al. Nasal carriage of and infection with staphylococcus aureus in HIV-infected patients. Ann Intern Med 1999;130:221-5
31. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group [see comment]. N Engl J Med 2001;344:11-16
32. Moss B, Squire J, Topley E. Nose and skin carriage of staphylococcus aureus in patients receiving penicillin. Lancet 1948;1:320-5
33. Troche G, Joly LM, Guibert M, Zazzo JF. Detection and treatment of antibiotic-resistant bacterial carriage in a surgical intensive care unit: a 6-year prospective survey. Infect Control Hosp Epidemiol 2005;26:161-5
34. Orsi GB, Raponi M, Franchi C, Rocco M, Mancini C, Venditti M. Surveillance and infection control in an intensive care unit. Infect Control Hosp Epidemiol 2005;26:321-5
35. Koning S, van Belkum A, Snijders S, van Leeuwen W, Verbrugh H, Nouwen J et al. Severity of nonbullous staphylococcus aureus impetigo in children is associated with strains harboring genetic markers for exfoliative toxin B, Panton-Valentine leukocidin, and the multidrug resistance plasmid pSK41. J Clin Microbiol 2003;41:3017-21
36. Melles DC, Gorkink RF, Boelens HA, Snijders SV, Peeters JK, Moorhouse MJ et al. Natural population dynamics and expansion of pathogenic clones of Staphylococcus aureus. J Clin Invest 2004;114:1732-40
37. Vriens M, Blok H, Fluit A, Troelstra A, Van Der Werken C, Verhoef J. Costs associated with a strict policy to eradicate methicillin-resistant staphylococcus aureus in a Dutch University Medical Center: a 10-year survey. European Journal of Clinical Microbiology & Infectious Diseases 2002;21:782-6
38. Lucet JC, Grenet K, Armand-Lefevre L, Harnal M, Bouvet E, Regnier B et al. High prevalence of carriage of methicillin-resistant staphylococcus aureus at hospital admission in elderly patients: implications for infection control strategies. Infect Control Hosp Epidemiol 2005;26:121-6
39. Jacobson JA, Stevens MH, Kasworm EM. Evaluation of single-dose cefazolin prophylaxis for toxic shock syndrome. Arch Otolaryngol Head Neck Surg 1988;114:326-7
40. Weimert TA, Yoder MG. Antibiotics and nasal surgery. Laryngoscope 1980;90:667-72
41. Jacobson JA, Kasworm EM. Toxic shock syndrome after nasal surgery. Case reports and analysis of risk factors. Arch Otolaryngol Head Neck Surg 1986;112:329-32
42. Abram AC, Bellian KT, Giles WJ, Gross CW. Toxic shock syndrome after functional endonasal sinus surgery: an all or none phenomenon? Laryngoscope 1994;104:927-31
43. Johnson JT, Myers EN, Thearle PB, Sigler BA, Schramm VL Jr. Antimicrobial prophylaxis for contaminated head and neck surgery. Laryngoscope 1984;94:46-51
44. Strong MS. Wound infection in otolaryngologic surgery and the inexpediency of antibiotic prophylaxis. Laryngoscope 1963;73:165- 84
45. Teichgraeber JF, Riley WB, Parks DH. Nasal surgery complications. Plast Reconstr Surg 1990;85:527-31
46. LawsonW, Kessler S, Biller HF. Unusual and fatal complications of rhinoplasty. Arch Otolaryngol 1983;109:164-9
47. Eschelman LT, Schleuning AJ 2nd, Brummett RE. Prophylactic antibiotics in otolaryngologic surgery: a double-blind study. Trans Am Acad Ophthalmol Otolaryngol 1971;75:387-94
48. Marples RR, Fulton JE, Leyden J, McGinley KJ. Effect of antibiotics on the nasal flora in acne patients. Arch Dermatol 1969;99:647-51
49. Brook I. Microbiology and management of sinusitis. J Otolaryngol 1996;25:249-56
50. Todd J, Fishaut M, Kapral F, Welch T. Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet 1978;2:1116-18
51. Jiang RS, Jang JW, Hsu CY. Post-functional endoscopic sinus surgery methicillin-resistant staphylococcus aureus sinusitis. Am J Rhinol 1999;13:273-7
52. Nakayama M, Tsunoda K, Igarashi M, Nishikawa K, Okazaki K. A case of toxic shock syndrome induced by MRSA after sinus surgery (in Japanese). Masui 1996;45:994-7
53. Kanaya H. Toxic shock syndrome after nasal surgery - Report of two cases. Otolaryngology. Head and Neck Surgery (Tokyo) 2005;77:55-59
54. Health Promotions Agency Communicable Diseases Surveillance Centre for the Department of Health. Results of the first three and a half years of the Department of Health's mandatory methicillin resistant staphylococcus aureus (MRSA) surveillance system in acute Trusts in England. 2005 http://www.dh.gov.uk/PublicationsAndStatistics/Publications/ PublicationsStatistics/Publications StatisticsArticle [10 May 2005]
55. Watters K, O'Dwyer TP, Rowley H. Cost and morbidity of MRSA in head and neck cancer patients: what are the consequences? J Laryngol Otol 2004;118:694-9